Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 1,847Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 6Banzel

02 3Inovelan

03 3Inovelan/Banzel

04 1Inovelon/Banzel

PharmaCompass

01

Brand Name : Inovelan/Banzel

Rufinamide

arrow
CPhI India 2024
Not Confirmed

Brand Name : Inovelan/Banzel

arrow
CPhI India 2024
Not Confirmed

Rufinamide

Main Therapeutic Indication : CNS & Anesthesia

Currency : USD

2020 Revenue in Millions : 222

2019 Revenue in Millions : 231

Growth (%) : -4

blank

02

Brand Name : Banzel

Rufinamide

arrow
CPhI India 2024
Not Confirmed

Brand Name : Banzel

arrow
CPhI India 2024
Not Confirmed

Rufinamide

Main Therapeutic Indication : CNS & Anesthesia

Currency : USD

2020 Revenue in Millions : 209

2019 Revenue in Millions : 203

Growth (%) : 3

blank

03

Brand Name : Inovelan/Banzel

Rufinamide

arrow
CPhI India 2024
Not Confirmed

Brand Name : Inovelan/Banzel

arrow
CPhI India 2024
Not Confirmed

Rufinamide

Main Therapeutic Indication : Neurology

Currency : USD

2021 Revenue in Millions : 85

2020 Revenue in Millions : 213

Growth (%) : -57

blank

04

Brand Name : Banzel

Rufinamide

arrow
CPhI India 2024
Not Confirmed

Brand Name : Banzel

arrow
CPhI India 2024
Not Confirmed

Rufinamide

Main Therapeutic Indication : Neurology

Currency : USD

2021 Revenue in Millions : 85

2020 Revenue in Millions : 200

Growth (%) : -54

blank

05

Brand Name : Banzel

Rufinamide

arrow
CPhI India 2024
Not Confirmed

Brand Name : Banzel

arrow
CPhI India 2024
Not Confirmed

Rufinamide

Main Therapeutic Indication : Neurology

Currency : USD

2022 Revenue in Millions : 62

2021 Revenue in Millions : 85

Growth (%) : -28

blank

06

Brand Name : Inovelan/Banzel

Rufinamide

arrow
CPhI India 2024
Not Confirmed

Brand Name : Inovelan/Banzel

arrow
CPhI India 2024
Not Confirmed

Rufinamide

Main Therapeutic Indication : Neurology

Currency : USD

2022 Revenue in Millions : 62

2021 Revenue in Millions : 85

Growth (%) : -28

blank

07

Brand Name : Inovelon/Banzel

Rufinamide

arrow
CPhI India 2024
Not Confirmed

Brand Name : Inovelon/Banzel

arrow
CPhI India 2024
Not Confirmed

Rufinamide

Main Therapeutic Indication : Neurology

Currency : USD

2023 Revenue in Millions : 30

2022 Revenue in Millions : 62

Growth (%) : -46

blank

08

Brand Name : Inovelan

Rufinamide

arrow
CPhI India 2024
Not Confirmed

Brand Name : Inovelan

arrow
CPhI India 2024
Not Confirmed

Rufinamide

Main Therapeutic Indication : Neurological/Mental Disorders

Currency : USD

2017 Revenue in Millions : 21

2016 Revenue in Millions : 18

Growth (%) : 16

blank

09

Brand Name : Banzel

Rufinamide

arrow
CPhI India 2024
Not Confirmed

Brand Name : Banzel

arrow
CPhI India 2024
Not Confirmed

Rufinamide

Main Therapeutic Indication : Neurological/Mental Disorders

Currency : USD

2017 Revenue in Millions : 159

2016 Revenue in Millions : 127

Growth (%) : 26

blank

10

Brand Name : Inovelan

Rufinamide

arrow
CPhI India 2024
Not Confirmed

Brand Name : Inovelan

arrow
CPhI India 2024
Not Confirmed

Rufinamide

Main Therapeutic Indication : Neurological/Mental Disorders

Currency : USD

2018 Revenue in Millions : 22

2017 Revenue in Millions : 20

Growth (%) : 9%

blank